[The treatment of prostatic carcinoma with cyproterone acetate].
Prostate gland carcinoma is a common and serious disease affecting males. Application of steroid and nonsteroid antiandrogens for the purpose of palliative management of prostate carcinoma dates back to 1973. It is endowed with a dual action-central (antigonadotrophic) and peripheral (antiandrogenic). The preparation is used in the form of monotherapy and as a combined therapeutic approach with the analogues of LHRH or orchiectomy. The obtained results undergo comparative assessment. It is believed that the combination cyproterone acetate with other hormonal preparations or orchiectomy yield optimal results in all groups of patients. One is impressed by the fact that the combination used at the onset of treatment is more effective than late inclusion of the second preparation.
Tsvetkov
M
M
Mladenov
D
D
Kumanov
Kh
Kh
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate
Lechenie na prostatniia kartsinom s tsiproteron-atsetat.